Literature DB >> 24816762

T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands.

Pinar Karasar1, Gunes Esendagli.   

Abstract

A conspicuous T cell infiltration is frequently observed in triple-negative and/or basal-like breast cancers. Since the immunological course of breast cancer is explicitly directed by helper T cells, this study aims to determine the influence of basal-like breast cancer (BLBC) cells on CD4(+) T cell responses. Co-cultures were established with breast cancer cell lines and CD4(+) T cells under stimulatory conditions. Helper T cell activation, proliferation, cytokine secretion, and differentiation were assessed. Protein and mRNA expression of PD-1 ligands were determined on breast cancer cell lines. Blockade assays were performed in order to determine the functional assets of PD-1 ligation. In contrast to luminal breast cancer cells, BLBC cells allowed CD4(+) T cell activation, proliferation, and IFN-γ secretion, but only to a certain extent. A substantial population of CD25(+)CD127(low/-) regulatory T (Treg) cells was also induced in BLBC co-cultures. In return, IFN-γ stimulated the upregulation of PD-L1 (B7-H1) and/or PD-L2 (B7-DC) inhibitory molecules on the basal-like cells. In prolonged periods of co-culturing, blockade of PD-1 ligands on BLBC cell lines impaired Treg differentiation, restored IL-2 secretion, and increased CD8(+) T cell activation. In conclusion, T helper responses were maintained by BLBC cells. On the other hand, IFN-γ secreted from Th1 and other immune cells upregulated the expression of PD-1 ligands on BLBC cells and modulated the immune reactions. Our results indicate the capacity of BLBCs to adapt to IFN-γ-mediated anti-tumor immune responses and to evade immunity via upregulation of PD-1 ligands.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24816762     DOI: 10.1007/s10549-014-2984-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  Prognostic and predictive value of PDL1 expression in breast cancer.

Authors:  Renaud Sabatier; Pascal Finetti; Emilie Mamessier; José Adelaide; Max Chaffanet; Hamid Raza Ali; Patrice Viens; Carlos Caldas; Daniel Birnbaum; François Bertucci
Journal:  Oncotarget       Date:  2015-03-10

2.  PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.

Authors:  François Bertucci; Pascal Finetti; Cécile Colpaert; Emilie Mamessier; Maxime Parizel; Luc Dirix; Patrice Viens; Daniel Birnbaum; Steven van Laere
Journal:  Oncotarget       Date:  2015-05-30

3.  Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.

Authors:  Ming Li; Anqi Li; Shuling Zhou; Yan Xu; Yaoxing Xiao; Rui Bi; Wentao Yang
Journal:  BMC Cancer       Date:  2018-01-02       Impact factor: 4.430

4.  Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters.

Authors:  Chenxi Yuan; Zhaoyun Liu; Qian Yu; Xinzhao Wang; Mengxue Bian; Zhiyong Yu; Jinming Yu
Journal:  Sci Rep       Date:  2019-10-07       Impact factor: 4.379

5.  Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival.

Authors:  Timuçin Erol; Nazli Eylem İmamoğlu; Büşra Aydin; Z Ekim Taşkiran; Güneş Esendağli; Kemal Kösemehmetoğlu; Ataç Baykal
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

6.  Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes.

Authors:  Nofar Erlichman; Tamir Baram; Tsipi Meshel; Dina Morein; Benny Da'adoosh; Adit Ben-Baruch
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.575

7.  Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.

Authors:  Renata Duchnowska; Rafał Pęksa; Barbara Radecka; Tomasz Mandat; Tomasz Trojanowski; Bożena Jarosz; Bogumiła Czartoryska-Arłukowicz; Wojciech P Olszewski; Waldemar Och; Ewa Kalinka-Warzocha; Wojciech Kozłowski; Anna Kowalczyk; Sherene Loi; Wojciech Biernat; Jacek Jassem
Journal:  Breast Cancer Res       Date:  2016-04-27       Impact factor: 6.466

Review 8.  The Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway.

Authors:  Laura Martin-Hijano; Bruno Sainz
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

9.  Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.

Authors:  Megan Kalpakoff; Stephanie Hund; Jeanette Musser; Charlotte Roach; Angeliki Apostolaki; Monika Vilardo; Lindsay Peltz; Brittany Watts; Chris LaPlaca; Siena Tabuena-Frolli; Michael A DiMaio; Rosanne Welcher; Karina Kulangara
Journal:  Appl Immunohistochem Mol Morphol       Date:  2021-10-01

10.  Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes.

Authors:  M Alper Kursunel; Ekim Z Taskiran; Ece Tavukcuoglu; Hamdullah Yanik; Funda Demirag; Beren Karaosmanoglu; Feyza Gul Ozbay; Aysegul Uner; Dorina Esendagli; Derya Kizilgoz; Ulku Yilmaz; Gunes Esendagli
Journal:  Cancer Immunol Immunother       Date:  2021-07-06       Impact factor: 6.968

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.